摘要
目的观察重组人生长激素(rhGH)在肝移植术后患者中的应用疗效。方法将24例肝移植术后患者随机分为rhGH治疗组和对照组,每组12例。两组患者术前状态无明显差异,肝功能Child分级均为C级,术前无全身感染性疾病。rhGH治疗组在术后第3天起连续7 d皮下注射重组人生长激素(8 IU／d),其他治疗同对照组。分别于术后第7、10、14天测定两组患者转氨酶、前白蛋白及免疫球蛋白水平。结果治疗组ALT、AST水平在术后第7、10、14天均低于对照组,在第7和第10天的差异有显著意义(P<0．05);前白蛋白水平在术后第7、10、14天均高于对照组,并在第10、14天的差异有显著意义(P<0．05)。治疗组在术后2周的白蛋白用量低于对照组,差异有统计学意义(P<0,05);而感染发生率低于对照组,在治疗期间两组均没有观察到急性排斥反应的发生。结论rhGH能促进肝移植术后早期肝功能的恢复及白蛋白的合成,改善患者术后营养状态,降低感染发生率,短期使用不增加急性排斥反应的发生率。
Objective To evaluate the use of recombinant human growth hormone （rhGH） in patients after liver transplantation. Methods In this study 24 postoperative liver transplantation patients were divided into two groups randomly ,the control group and the rhGH group, in which 8 U rhGH was given daily beginning the 3rd day posttransplant for 7 days. There was no significant difference in the preoperative status between the two groups. There was no pretransplant systemic infection and the liver function was Child C in all patients. Posttransplantation ALT,AST, Pre-ALB and immune globin at the 7th ,10th and 14th day were detected. Results AI,T and AST levels at the 7th and 10th day after operation were significantly lower in the rhGH group than in the control group（ P 〈 0. 05） while at the 14th day there was no statistic difference . At 10th and 14th day after operation the pre-ALB level was significantly higher in the rhGH group than the control group （ P 〈 0. 05 ）. The total usage of albumin was lower in rhGH group than in the control group （ P 〈 0. 05 ）. The incidence of infection was lower in rhGH group. Acute rejection was not observed in all patients. Conclusion rhGH can accelerate the recovery of liver function after liver transplantation, promote the synthesis of protein, improve the nutrition status after operation and reduce the incidence of infection. The risk of acute rejection was not observed when rhGH was used in short time.
出处
《中华普通外科杂志》
CSCD
北大核心
2006年第10期742-744,共3页
Chinese Journal of General Surgery
关键词
肝移植
人生长激素
Liver transplantation
Human growth hormone
